SCHEMBL20187523

SCHEMBL20187523

Cc1cncc2nc[nH]c(=O)c12

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 9/20 0.59
KDM4A O75164 1/20 0.47
KDM4B O94953 1/20 0.47
KDM5C P41229 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM5B Q9UGL1 1/20 0.47
KDM3A Q9Y4C1 1/20 0.47
PDPK1 O15530 4/20 0.42
CHEK1 O14757 1/20 0.42
PIM1 P11309 1/20 0.42
RPS6KA3 P51812 1/20 0.42
CA12 O43570 1/20 0.39
ALOX15 P16050 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CA9 Q16790 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
ACVR1 Q04771 2/20 0.38
BCAT2 O15382 1/20 0.37
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17164000 0.78 KDM4A (0.47) PARP1KDM4AKDM4BKDM5CKDM4C
SCHEMBL4454926 0.77 KDM4A (0.44) PARP1KDM4AKDM4BKDM5CKDM4C
SCHEMBL2317275 0.74 PARP1 (1.00) PARP1KDM4AKDM4BKDM5CKDM4C
SCHEMBL29563063 0.74 PARP1 (1.00) PARP1KDM4AKDM4BKDM5CKDM4C
SCHEMBL349975 0.74 PARP1 (0.59) PARP1PDPK1CHEK1PIM1RPS6KA3
SCHEMBL15508430 0.72 KDM4A (0.36) PARP1KDM4AKDM4BKDM5CKDM4C
SCHEMBL31330715 0.72 PARP1 (0.61) PARP1SMN1; SMN2TNKS2ALDH1A1
SCHEMBL11485473 0.71 PARP1 (0.60) PARP1PDPK1CHEK1PIM1RPS6KA3
SCHEMBL21550782 0.71 PARP1 (0.60) PARP1PDPK1CHEK1PIM1RPS6KA3
SCHEMBL20435417 0.70 PARP1 (0.54) PARP1PDPK1CHEK1PIM1RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768260-B1 OXADIAZOLE COMPOUNDS AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS HOFFMANN LA ROCHE (CH) 2025-10-08 EP disclosed
US-20250122184-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2025-04-17 US disclosed
US-12202824-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2025-01-21 US disclosed
CN-114874209-B Oxadiazole transient receptor potential channel inhibitors 豪夫迈·罗氏有限公司 2024-08-06 CN disclosed
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2023-05-23 US disclosed
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2023-05-23 US disclosed
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2023-05-23 US disclosed
US-20230121700-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2023-04-20 US disclosed
CN-114874209-A Oxadiazole transient receptor potential channel inhibitors 豪夫迈·罗氏有限公司 2022-08-09 CN disclosed
CN-110461838-B Oxadiazole transient receptor potential channel inhibitors 豪夫迈·罗氏有限公司 2022-05-06 CN disclosed
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
EP-3544979-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS H. Hoffnabb-La Roche Ag (CH) 2019-10-02 EP disclosed
WO-2019182925-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-26 WO disclosed
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed
US-20190284189-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed
US-20190284189-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed
WO-2018096159-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-05-31 WO disclosed
WO-2018096159-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 PARP1 4192/4885KDM4A 4306/4885KDM4B 4251/4885
US-12202824-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 PARP1 3390/4885KDM4A 3596/4885KDM4B 3912/4885
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, P2RX3 PARP1 3336/4885KDM4A 3354/4885KDM4B 3642/4885
US-20190284189-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 PARP1 4175/4885KDM4A 4193/4885KDM4B 4389/4885
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 PARP1 3390/4885KDM4A 3596/4885KDM4B 3912/4885
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 PARP1 3390/4885KDM4A 3596/4885KDM4B 3912/4885
US-20230121700-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 PARP1 3390/4885KDM4A 3596/4885KDM4B 3912/4885
US-20250122184-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 PARP1 3390/4885KDM4A 3596/4885KDM4B 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.